I would like to thank and congratulate the countless individuals, including CorMedix employees, contractors and consultants who worked tirelessly over the last decade to bring this innovative drug product to patients in need. Our field team has been actively engaged in discussions with numerous hospitals and health systems in the inpatient setting, and I'm pleased with the progress we've made in only a few weeks of field deployment. Our initial core focus is targeting approximately 900 hospital facilities where those facilities are responsible for roughly 65% of inpatient dialysis procedures in the US. As a frame of reference, this represents only about 12% of US hospitals but accounts for the majority of the potential DefenCath inpatient market opportunity.

Our field team has met with more than half of our targeted institutions. And as of today, roughly 50 key accounts representing more than 200 individual hospitals have recommended DefenCath for formulary review in the coming months at their respective institutions. In addition, a few hospitals have already added DefenCath on a non-formulary basis, while P&T formulary review remains pending. As we have communicated previously, the inpatient process to obtain formulary inclusion followed by facility adoption and product orders can span several months. To that extent, we have guided that we do not expect material inpatient sales in the second quarter, and we'll look for inpatient uptake to increase as we move throughout the year. On the outpatient front, we remain on track to commence outpatient commercialization in July.

We were pleased that CMS took timely action on our TDAPA application, which ensures that Medicare fee-for-service reimbursement claims submitted by outpatient providers beginning July 1 will be reimbursed by CMS. We are also very happy to announce our first outpatient procurement contract with ARC Dialysis. One of the largest regional dialysis providers in the Southeast US. We are currently engaged in commercial discussions with 8 of the top 10 US dialysis providers to help to communicate new procurement contracts over the next few months. From a guidance standpoint, we reiterate our operating expense guidance disclosed previously of $15 million to $18 million per quarter for calendar year 2024. And continue to believe we can achieve breakeven profitability on a run rate basis by the end of 2024, if we achieve our base case assumptions for product utilization.

Our base assumptions do include limited adoption by at least one of the two large dialysis organizations as well as some utilization from midsize and smaller facilities. At present, we are in advanced stages of negotiations with one of the two large operators for the implementation of DefenCath as well as several midsize and smaller operators, and we are working through their respective operational dynamics as we structure our commercial offering to each of them. There is a significant amount of planning and logistics involved in DefenCath implementation, especially for larger organizations, and we are working with those organizations to understand how we can better support patient adoption within their facilities. As we roll out our launch and continually gauge progress against our base case assumptions, we intend to be prudent with our cash management.

With this in mind, we are taking practical steps from a balance sheet management standpoint to provide ourselves with options in the event any additional capital is beneficial or needed down the road, be it to fund M&A and business development, organic growth or additional working capital for accounts receivable and inventory. To that extent, today, we are announcing a Letter of Intent with a large US based lender for a revolving credit facility of up to $25 million, which allows CorMedix to access certain tranches of debt depending on our run rate of accounts receivable. The credit facility will not require us to draw any minimum amount and will be a helpful instrument for managing our balance sheet and working capital in a non-dilutive manner.

We expect to close the revolving credit facility over the next few weeks. Simultaneously with the credit facility Letter of Intent today, filing to renew our expiring shelf registration statement as well as replace the expired ATM facility. My objective is to be able to make cost of capital based decisions between equity and debt, should any additional capital be required in the future, keeping focus on minimizing shareholder dilution when possible. Matt will discuss the company's cash position in more detail momentarily. In terms of our plans for label expansion, as we communicated previously, we have submitted to FDA a Type C meeting request to discuss a pathway to additional indications. FDA has accepted that meeting request, and we anticipate receiving feedback from the agency on our proposals by end of June.

We have also used this Type C meeting request as an opportunity to readdress the pediatric study requirement that is outlined in our approval letter. Based upon feedback from potential study investigators, we do not believe it will be feasible to run the pediatric study in hemodialysis in a manner previously discussed with FDA. FDA has granted us an extension on our final study protocol, and we expect to have feedback on a revamped pediatric study or a potential waiver by the end of June as well. From a label expansion standpoint, we have elected to propose a clinical pathway for total parenteral nutrition or TPN, as a first step before we put forward a proposal for any uses of oncology. Once we have feedback from FDA and alignment on our proposal related to TPN, we can then craft a proposed study for use in oncology.

The decision to prioritize TPN for submission and FDA discussion was based upon the expected timing and cost of the clinical program being proposed relative to the expected market size. Though oncology is potentially a larger market opportunity, we've elected to prioritize the potentially faster program first. Assuming acceptable feedback from the agency in June, anticipate submission of an oncology proposal to FDA later this year. Lastly, from a supply chain perspective and our efforts to derisk our reliance on a single finished dose manufacturer, earlier this week, we submitted a supplement to our NDA, adding Siegfried Hameln site as an alternate manufacturer. Pending a successful FDA review of the supplement, we anticipate Siegfried coming online as a manufacturer as early as the end of '24.

CorMedix has now grown to approximately 90 employees, and I'm proud of what we have accomplished over these recent months. I would now like to turn the call over to Matt to discuss the company's first quarter financial results and financial position. Matt?

Matt David: Thanks, Joe, and good morning, everyone. I am pleased to be here today to provide an overview of our first quarter 2024 financial results as well as an update on CorMedix's cash position. The company has followed its quarterly report on Form 10-Q for the quarter ended March 31, 2024. I urge you to read the information contained in the report for a more complete discussion of our financial results. With respect to our first quarter of 2024 financial results, our net loss was approximately $14.5 million or $0.25 per share compared with the loss of $10.6 million or $0.24 per share in the first quarter of 2023. The higher net loss recognized in 2024 compared with 2023 was driven by an increase in SG&A expenses versus the first quarter of 2023, partially offset by the sale of New Jersey NOLs over $1.4 million.

Operating expenses in the first quarter of 2024 increased approximately 44% to $15.9 million compared with $11 million in the first quarter of 2023. R&D expense decreased by approximately 75% to $0.8 million, driven by the approval of DefenCath. As a result of the post-FDA approval commercial operations, costs related to medical affairs and certain personnel expenses that supported R&D efforts prior to the FDA approval of DefenCath have been recognized in SG&A expense. SG&A expense increased approximately 98% to $15 million in the first quarter of 2024 compared with $7.6 million in the first quarter of 2023. This increase was primarily attributable to increases in personnel expenses due to the hiring of sales force, medical affairs and marketing personnel.

In addition, certain costs related to medical affairs and certain personnel expenses that had been previously recognized in R&D are now recognized in SG&A following the FDA approval of DefenCath. To a lesser extent, the increase was also driven by increases in non-cash charges for stock-based compensation and increases in consulting fees. We recorded net cash used in operations during the first quarter of 2024 of $17.3 million compared with net cash used in operations of $10.4 million in the first quarter of 2023. The increase is primarily driven by an increase in net loss and decreases in accrued expenses and accounts payable. The company has cash and cash equivalents of $58.6 million as of March 31, 2024. As we have discussed previously, we expect our operating expenses, especially SG&A, to remain at increased levels given the growth of the company and the cost driven by the commercial launch of DefenCath.

CorMedix anticipates 2024 quarterly operating expenses to range from around $15 million to $18 million to support commercial infrastructure and the ongoing launch of DefenCath. We believe our cash, cash equivalents, short-term investments and projected future operating cash flow gives the company the ability to fund operations for at least 12 months and to fund the commercial launch of DefenCath through to anticipated profitability, which may occur on a run rate basis by the end of 2024, assuming we were able to achieve our internal base case assumptions for DefenCath demand, uptake, net pricing and reimbursement. I will now turn the call back over to Joe for closing remarks. Joe?

Joe Todisco: Thanks, Matt. CorMedix is executing well on our key objectives and is hopeful to provide more substantive updates on sales progress on our next quarterly call in August. I appreciate everyone's continued support of CorMedix, and I'm happy to now take questions.

See also

30 Highest Paid Jobs and Occupations in the US and

15 Jobs That Will Be in Demand in 2030.

To continue reading the Q&A session, please click here.